<DOC>
	<DOCNO>NCT00873353</DOCNO>
	<brief_summary>The purpose study determine efficacy treatment erlotinib combination capecitabine patient advance pancreatic cancer .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Tarceva Capecitabine Advanced Pancreatic Cancer Patients</brief_title>
	<detailed_description>This efficacy determine objective response rate follow RECIST criterion .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Ability understand willingness sign write informed consent 2 . Informed consent sign patient 3 . Age &gt; 18 year old 4 . Able fulfill criterion protocol 5 . Performance status Karnofsky ≥ 60 % ( ECOG 02 ) 6 . Life expectancy ≥ 12 week 7 . Histologically cytological ( exclude endocrine pancreatic tumour ) , metastatic ( stage IV ) , follow 6th edition TNM classification 8 . Measurable disease follow RECIST criterion 9 . Adequate bone marrow function determine : Absolute Neutrophil account ( ANC ) ≥ 1,5 x 109/L Platelets : ≥ 100 x 109/L Hemoglobin : ≥ 9 g/dL . 10 . Adequate liver function , determine : Serum bilirubin ( total ) : ≤ 1,5 x LSN AST , ALT ≤ 2,5 x LSN patient without liver metastasis . In patient liver metastasis ≤ 5 x LSN 11 . Adequate renal function , determine : Clearance creatinine &gt; 60.0 ml/min 12 . Men woman potentially fertile ( include postmenopausal woman amenorrheic least 24 month study ) use adequate contraceptive method ( oral contraceptive , intrauterine disposal , barrier method together spermicide surgery sterilization ) 1 . Local pancreatic cancer ( stage IAIIB ) locally advance cancer ( stage III ) , follow TNM 6th edition classification . Patients metastatic disease relapse initial diagnosis local advance disease could include study . 2 . Evidence medullary compression , carcinomatosis meningitis brain metastasis . In case clinical suspicious brain metastasis mandatory perform brain TAC/MR 4 week prior inclusion . 3 . Previous systemic treatment metastasis pancreas cancer . Adjuvant chemotherapy permit ≥ 4 week prior de inclusion . All toxicity adjuvant treatment must solve inclusion confirm disease progression ( metastatic disease ) alter adjuvant treatment 4 . Primary tumour Developer 5 year previous inclusion , except situ cérvix carcinoma skin basocellular cancer properly treat 5 . Noncontrolled hypertension cardiovascular disease clinically significant ( active ) : Cerebrovascular accident/ictus ( ≤ 6 week prior inclusion ) Heart attack ( ≤ 6 month prior inclusion ) Instable angina Congestive cardiac insufficiency ( grade II superior follow New York Heart Association ( NYHA ) Severe cardiac arrhythmia require medication 6 . Significant ophthalmology anomaly 7 . Deficit dihydropyrimidine dehydrogenase ( DPD ) 8 . Unable take oral drug . Previous surgical process affect absorption make need intravenous feed parenteral nutrition lipid . 9 . Pregnancy woman latency period . Negative pregnancy test need 7 day prior initiation drug study 10 . Actual 30 day previous study treatment investigational drug participation trial 11 . Previous treatment Capecitabine EGFR inhibitor . 12 . Any disease , metabolic disease 13 . Known hypersensibility study drug component , 5fluorouracile</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Metastatic Adenocarcinoma Pancreas</keyword>
</DOC>